Beta Bionics (BBNX) Bank of America 2025 Healthcare Conference summary

Financial performance and guidance

• Q1 revenue exceeded expectations by 9%, with new patient starts surpassing forecasts by about 450 patients.

• Pharmacy channel adoption exceeded expectations, leading to increased annual guidance for pharmacy reimbursement.

• Revenue guidance for the year was raised to $82–87 million, reflecting both the Q1 beat and higher pharmacy adoption.

• Gross margin guidance increased to 50–53%, supported by lower bill of materials and greater manufacturing scale.

• Tariff impacts are minimal due to exemptions for custom components; only trivial non-custom parts are affected.

Product innovation and market adoption

• iLet continues to gain traction as a differentiated insulin pump, with strong patient and provider feedback.

• Recent launches include Libre 3 Plus, Color iLet, and the Bionics Circle app, all contributing to market momentum.

• Integration with Libre 3 was a first in the U.S., providing a competitive advantage.

• Expansion to 63 territories, with 20 added in Q1 2025, though new territories had no material Q1 revenue impact.

• New sales territories are expected to begin contributing in Q2 and beyond.

Channel strategy and patient mix

• Pharmacy channel offers a subscription model, generating over three times more revenue per patient over four years compared to DME.

• Pharmacy channel lowers patient out-of-pocket costs, driving higher new patient starts.

• 20–25% of new patients in Q1 were from the type 2 diabetes population, indicating growing adoption in this segment.

• The percentage of new patient starts through pharmacy is a key metric, reflecting improved access and lower copays.

• PBM contracts, plan adoption, and logistics are all critical steps for pharmacy channel growth.